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Abstract 
Cyclization of 4-(2-halophenyl)-1H-pyrazolo[3,4-b]quinolines 3a-b and 9a-9b provided two 
regioisomeric compounds: 6-phenyl-6H-5,6,7-triazadibenzo[f,h]naphtho[3,2,1-cd]azulenes 4,10 
and 1,3-diphenyl-3H-indeno[1,2,3-de]pyrazolo[3,4-b]quinolines 2,11. All of them are considered 
as new building blocks for optoelectronic materials. The two-step synthesis utilized readily 
available starting materials. 
 
Keywords: Azafluoranthene, annulation, cyclodehydrohalogenation, 1H-pyrazolo[3,4-
b]quinoline  
 
 
 
Introduction 
 
Pyrazolo[3,4-b]quinolines (PQs) are known for their antiviral (HSV-1, HSV-2, CMV, VZ and 
EB) properties,1 as COX inhibitors,2 inhibitors of oncogenic Ras,3 interferon inducing agents,4 
antimicrobials,5 antimalarials,6 and potent apoptosis inducers.7 PQs also belong to a class of 
highly fluorescent compounds which emit mostly in the blue spectral range and have been 
classified as promising materials for optoelectronics.8 Attempts have been made to red-shift of 
their fluorescence spectra,9  by changing substituents and introduction of the additional N-atom 
into the central aromatic ring. In this project we have paid attention to polycyclic aromatic 
hydrocarbons (PAHs) of a high photoluminescence quantum yields useful for OLEDs.10 
Generally speaking, an increase in the extent of the π-electron system (i.e. degree of conjugation) 
leads to a shift of the absorption and fluorescence spectra to longer wavelengths and to an 
increase in the fluorescence quantum yield.11 In the case of PQs the only possibility left to 
achieve the expected effect is to increase the number of fused rings. In this paper we disclose a 
practical synthesis of azafluoranthenes and heterocyclic analogues of azulene derived from PQs. 
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These new heterocycles could be potential building blocks in supramolecular chemistry and 
luminophores for OLEDs.12
 
 
Results and Discussion 
 
Since prerequisite PQ 1 could not be simply prepared by the method formerly developed,13 which 
eventually would allow the formation of 2, its isomeric 4-(2-chlorophenyl)-1,3-diphenyl-1H-
pyrazolo[3,4-b]quinoline 3a was prepared from 2-chlorobenzaldehyde, 1,3-diphenylpirazol-5-
one and aniline. The isomer was then cyclized according to Clar.14 Instead of the expected 
derivative of 3-azafluoranthene 2, only a seven-membered heterocycle 4 was formed. To confirm 
our result, we prepared 4-(2-chlorophenyl)-3,7-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]quinoline 
5. The attempted cyclodehydrohalogenation in 5 on reflux in quinoline/KOH failed. In another 
approach to facilitate the ring closure we also synthesized 7, but its cyclization did not yield any 
traces of 8 (Scheme 1). 
 
 
Scheme 1 
 
Prolonged reflux of 3a,b in quinoline did not produce nor 2 or 4. Therefore, the presence of 
halogen atom and a strong inorganic base appeared indispensable for the ring closure. Our 
attempt involving the use of a powerful hindered organic base, 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) in different solvents,15 as suggested in the literature did not give appreciable results 
because of the uncompleted conversion to 4. Finally, we found that the easiest approach to the 
synthesis of the regioisomer 2 involved cyclization of 4-(2-bromophenyl)-1,3-diphenyl-1H-
pyrazolo[3,4-b]quinoline 3b by modified Wegner16 procedure  where P(t-Bu)3 was used as a 
ligand instead of P(Cy)3. This reaction furnished indeno-annelated product 2 with a reasonable 
yield and only a trace of seven-membered ring system 4 was formed (TLC monitoring). Contrary 
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to it, heating of 3b in KOH/quinoline gave exclusively 4. The same reactions conditions were 
also examined for 3a. This delivered a mixture of 2 and 4, with a low yield. More recently, the 
group of Scott has proven that even the chlorine atom could be utilized in the intramolecular 
cyclization using different Pd catalysts.17 To additionally confirm the site of cyclization, we 
readily obtained two halo derivatives 9a,b (Scheme 2). They were treated in the same manner as 
mentioned above. The characterization of 10 and 11 was achieved by NMR spectroscopy 
according to the following strategy: i) the spectrum of the regioisomer 11 revealed two doublets 
 
 
Scheme 2 
 
originating from a free 3-p-methoxyphenyl moiety; ii) the analysis of 10 provided evidence for 
the cross-annulation of the 3-ring. The plausible explanation accounting for the formation of 4 
(or 10) is depicted below (Scheme 3): 3a,b (9a,b) treated with KOH gives a reactive 
intermediate (o-benzyne) 13a. In the present case 13a has the possibility of reacting in two 
different orientations: to close the five-membered ring or to attack the adjacent phenyl moiety. 
The latter route seems to be more probable to bring the aryne within bonding distance. Thus a 
diradical 13b attacks the 3-phenyl ring creating σ bond with hydrogen abstraction.  
 
 
Scheme 3 
 
Similar transformation was observed by Cram and coworkers.18 Indeno[1,2,3]-annelated 2 (or 
11) products are examples of an intramolecular arylation to form the five-membered rings. It is 
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often considered that such cyclization involves intramolecular electrophilic attack of the 
arylpalladium(II) moiety 15 on another aromatic ring in the key intermediate.15b In this case the 
six-membered geometry of the intermediate 16 should facilitate this ring closure and disfavor the 
formation of seven-membered analogues. On the other hand, the presence of the electron-
withdrawing N-atom should make this assumption inconsistent with an electrophilic aromatic-
substitution mechanism. Recently, another authors proposed a quite different mechanism 
proceeding by abstraction of a proton of the arylated ring by the base in a process in which the 
formation of the metal-carbon bond is concerted with the breaking of the carbon-hydrogen 
bond.19 They studied the intramolecular palladium-catalyzed arylation of on a variety of 
bromobenzyldiarylmethane systems. They found that electron-withdrawing substituents favored 
this reaction. In our case the 5-position of 3b is more acidic because of the electronegative N-
atom of the pyridine than ortho-protons of the proximal phenyl ring at the 3-position. As a result 
this leads to the nearly exclusive formation of five-membered regioisomers. 
 
 
Conclusions 
 
In summary, this preliminary report describes two new, efficient synthetic routes to a variety of 
aromatic structures containing five- and seven-membered rings. The starting materials are cheap, 
readily available and the compounds can be prepared in 2 steps in most cases without 
chromatographic separation. The remarkable is the easy formation of seven-membered aromatic 
ring system which is very rare.20 The latter also can be considered as the example of topological 
chemical defects spotted in carbon nanotubes (pentagon-heptagon pair).21 Both annulated 
structures can be derived from the same starter. Further studies are under way to expand the 
scope of the present method, and to use the products for further conversion as well as for the 
OLED construction. 
 
 
Experimental Section 
 
1,3-Di(aryl)- and 1-aryl-3-methyl-4-(2-halophenyl)-1H-pyrazolo[3,4-b]quinolines 3. General 
procedure 
Equimolar amounts (10 mmol) of aniline, 1,3-diphenylpyrazolin-5-one and 2-halobenzaldehyde 
were refluxed for 2 h with TLC monitoring in ethylene glycol (20 mL). After cooling the mixture 
was treated with MeOH. It was refluxed for 30 min, followed by cooling and sonication in a cold 
water bath for 1 h. The yellow precipitate was collected. Only bromoderivative 3b was further 
purified by column chromatography (alumina, toluene) because it was contaminated with a little 
amount of debrominated product. 
4-(2-Chlorophenyl)-1,3-diphenyl-1H-pyrazolo[3,4-b]quinoline (3a). Light yellow solid; yield 
1.64 g (38 %); mp = 200−202 °C;  UV (MeCN): λmax [nm] = 398 nm; Fluorescence (MeCN) λmax 
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[nm] = 481; 1H NMR (300 MHz, CDCl3) δ 7.06−7.25 (m, 7H), 7.26−7.35 (m, 3H), 7.40 (ddd, 
1H, J = 8.7, 6.6, 1.2 Hz), 7.58 (t, 2H, J = 7.5 Hz), 7.64 (ddd, 1H, J = 8.7, 1.5, 0.6 Hz), 7.78 (ddd, 
1H, J = 8.7, 6.6, 1.5 Hz), 8.27 (ddd, 1H, J = 8.7, 1.2, 0.6 Hz), 8.62 (d, 2H, J = 9.0 Hz); Anal. 
Calcd. for C28H18ClN3; C, 77.86; H, 4.20; N, 9.73. Found: C, 77.39; H, 4.56; N, 9.71. 
4-(2-Bromophenyl)-1,3-diphenyl-1H-pyrazolo[3,4-b]quinoline  (3b). Light yellow solid; yield 
1.67 g (35%); mp = 204−206 °C;  1H NMR (300 MHz, CDCl3) δ 7.06−7.26 (m, 8H), 7.32 (t, 1H, 
J = 7.5 Hz), 7.39 (ddd, 1H, J = 8.1, 6.6, 1.5 Hz), 7.50−7.53 (m, 1H), 7.57 (t, 2H, J = 7.5 Hz), 
7.62 (ddd, 1H, J = 9.0, 1.2, 0.9 Hz), 7.77 (ddd, 1H, J = 9.0, 6.6, 1.5 Hz), 8.26 (ddd, 1H, J = 9.0, 
1.2, 0.9 Hz), 8.63 (d, 2H, J = 8.7 Hz); Anal. Calcd. for C28H18BrN3; C, 70.60; H, 3.81; N, 8.82. 
Found: C, 70.60; H, 4.17; N, 8.97. 
4-(2-Chlorophenyl)-3,7-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]quinoline (5). This compound 
was prepared following general procedure for compounds 3 using equimolar (10 mmol) of 3-
methylaniline, 1-phenyl-3-methylpyrazolin-5-one and 2-chlorobenzaldehyde. Yellow solid; yield 
1.19 g (31%); mp = 147–148 °C; 1H NMR (300 MHz, CDCl3) δ 2.13 (s, 3H), 2.57 (s, 3H), 7.20 
(dd, 1H, J = 8.7, 1.8 Hz), 7.26 (t, 1H, J = 7.5 Hz), 7.37 (dd, 1H, J = 7.5, 1.8 Hz), 7.42–7.57 (m, 
5H), 7.62 (dd, 1H, J = 7.8, 1.2 Hz), 8.00 (t, 1H, J = 0.6 Hz), 8.51 (d, 2H, J = 8.7 Hz); Anal. 
Calcd. for C24H18ClN3; C, 75.09; H, 4.73; N, 10.95. Found: C, 74.98; H, 4.95; N, 10.93. 
6-Butyl-4-(naphthalen-1-yl)-1,3-diphenyl-1H-pyrazolo[3,4-b]quinoline (7). This compound 
was prepared following general procedure for compounds 3 using equimolar (10 mmol) of 4-n-
butylaniline, 1,3-diphenylpyrazolin-5-one and 1-naphthaldehyde. Light yellow solid; yield 2.45 g 
(49%); mp = 152–153 °C; 1H NMR (300 MHz, CDCl3) δ 0.80 (t, 3H, J = 7.2 Hz), 1.16–1.28 (m, 
2H), 1.44–1.54 (m, 2H), 2.56 (t, 2H, J = 7.5 Hz), 6.74 (t, 2H, J = 7.5 Hz), 6.80–6.84 (m, 2H), 
6.95 (t, 1H, J = 7.2 Hz), 7.23–7.34 (m, 6H), 7.39–44 (m, 1H), 7.58 (t, 2H, J = 7.5 Hz), 7.64 (dd, 
1H, J = 9.0, 1.8 Hz), 7.79–7.83 (m, 2H), 8.21 (d, 1H, J = 8.7 Hz), 8.64 (d, 2H, J = 8.7 Hz); Anal. 
Calcd. for C36H29N3; C, 85.85; H, 5.80; N, 8.34. Found: C, 85.86; H, 5.89; N, 8.55. 
 
6-Ethyl-4-(2-halophenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]quinoline 9a,b. 
General procedure 
Equimolar amounts (10 mmol) of 4-ethylaniline, 3-(4-methoxyphenyl)-1-phenylpyrazolin-5-one 
and 2-halobenzaldehyde were refluxed for 2 h with TLC monitoring in ethylene glycol (20 mL). 
The mixture was cooled and treated with MeOH. Next it was refluxed for 30 min, followed by 
cooling and sonication in a cold water bath for 1 h. The yellow precipitate was collected. 
4-(2-Chlorophenyl)-6-ethyl-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]quinoline 
(9a). Light yellow solid;  yield 2.45 g (50%); mp = 149–151 °C; 1H NMR (300 MHz, CDCl3) δ 
1.24 (t, 3H, J = 7.5 Hz), 2.73 (q, 2H, J = 7.5 Hz), 3.77 (s, 3H, OCH3), 6.62 (d, 2H, J = 8.7 Hz), 
7.13–7.20 (m, 4H), 7.27–7.38 (m, 4H), 7.57 (t, 2H, J = 7.5 Hz), 7.66 (dd, 1H, J = 8.7,1.8 Hz), 
8.18 (d, 1H, J = 9.0 Hz), 8.61 (d, 2H, J = 8.7 Hz); Anal. Calcd. for C31H24ClN3O; C, 75.99; H, 
4.94; N, 8.58. Found: C, 75.63; H, 5.40; N, 8.55. 
4-(2-Bromophenyl)-6-ethyl-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]quinoline 
(9b). Light yellow solid; yield 2.40 g (45%); mp = 164–165 °C; 1H NMR (300 MHz, CDCl3) δ 
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1.24 (t, 3H, J = 7.5 Hz), 2.73 (q, 2H, J = 7.5 Hz), 3.76 (s, 3H, OCH3), 6.62 (d, 2H, J = 9.0 Hz), 
7.11–7.24 (m, 5H), 7.30 (t, 1H, J = 7.5 Hz), 7.34 (dd, 1H, J = 8.1, 0.6 Hz), 7.54–7.59 (m, 3H), 
7.65 (dd, 1H, J = 9.0, 2.1 Hz), 8.18 (d, 1H, J = 8.7 Hz), 8.62 (d, 2H, J = 8.7 Hz); Anal. Calcd. for 
C31H24BrN3O; C, 69.67; H, 4.53; N, 7.86. Found: C, 69.14; H, 4.68; N, 8.07. 
 
Cyclization of 3a and 9a. General procedure 
3a (0.50 g, 1.16 mmol), powdered KOH (1.95 g, 34.8 mmol) and quinoline (20 mL) were 
refluxed for 3−4 h until reaction was completed (TLC, toluene). After cooling, the orange 
solution was treated with 10% hydrochloric acid (100 mL) and extracted with toluene (2 x 20 
mL). The organic phase was washed with saturated aqueous NaCl solution, dried over anhydrous 
MgSO4 and evaporated to dryness. The residue was dissolved in chloroform and MeOH was 
added dropwise on sonication in a cold water bath (1 hour). A precipitate was filtered off. 
6-Phenyl-6H-5,6,7-triazadibenzo[f,h]naphtho[3,2,1-cd]azulene (4). Yellow solid; yield 307 
mg (67%); mp = 203−205 °C; IR (KBr) 3100, 1597, 1499, 1461, 1400, 1138, 737, 689 cm-1; UV 
(MeCN): λmax [nm] = 446 nm; Fluorescence (MeCN) λmax [nm] = 542; 1H NMR (300 MHz, 
CDCl3) δ 7.30 (t, 1H, J = 7.5 Hz), 7.38−7.53 (m, 5H), 7.58 (t, 2H, J = 7.5 Hz), 7.70−7.75 (m, 
2H), 7.80−7.83 (m, 1H), 7.86 (dd, 1H, J = 8.1, 1.2 Hz), 8.16 (dd, 1H, J = 8.4, 0.6 Hz), 8.31−8.34 
(m, 1H), 8.44 (dd, 1H, J  = 8.7, 0.9 Hz), 8.60 (d, 2H, J = 8.7 Hz); 13C NMR (75 MHz, CDCl3) δ 
120.31, 120.95, 121.82, 123.69, 125.16, 127.45, 127.54, 127.61, 128.62, 128.88, 129.01, 129.11, 
129.52, 129.98, 132.08, 133.47, 134.25, 134.64, 135.40, 138.17, 140.13, 140.68, 142.12, 143.70, 
150.49, 150.65; MS (FAB) m/z 396 (M++H); Anal. Calcd. for C28H17N3; C, 85.04; H, 4.33; 
N,10.63. Found: C, 84.92; H, 4.46; N, 10.61. 
10-Ethyl-2-methoxy-6-phenyl-6H-5,6,7-triazadibenzo[f,h]naphtho[3,2,1-cd]azulene (10). 
Yellow–orange solid; yield 998 mg (71%); mp = 137−139 °C; 1H NMR (300 MHz, CDCl3) δ 
1.32 (t, 3H, J = 7.5 Hz), 2.83 (q, 2H, J = 7.5 Hz), 3.91 (s, 3H, OCH3),7.03 (dd, 1H, J = 9.0, 2.7 
Hz), 7.27 (t, 1H, J = 7.5 Hz), 7.32 (d, 1H, J = 2.7 Hz), 7.41 (td, 1H, J = 7.8, 1.5 Hz), 7.48 (td, 
1H, J = 7.5, 1.5 Hz), 7.55 (t, 2H, J = 7.5 Hz), 7.59 (dd, 1H, J = 9.0, 2.1 Hz), 7.76 (dd, 1H, J = 
7.8, 1.5 Hz), 7.89 (dd, 1H, J = 7.8, 1.5 Hz), 8.08 (d, 1H, J = 8.7 Hz), 8.22 (d, 1H,  J = 0.9 Hz), 
8.23 (d, 1H, J = 8.7 Hz), 8.58 (d, 2H, J = 8.7 Hz); 13C NMR (75 MHz, CDCl3) δ 15.36, 28.98, 
55.46, 114.71, 116.99, 120.09, 120.91, 121.82, 124.82, 124.85, 126.81, 127.64, 128.97, 129.19, 
129.43, 131.38, 134.05, 134.93, 135.20, 139.47, 139.68, 140.32, 140.50, 141.22, 143.64, 149.42, 
150.50, 159.89; Anal. Calcd. for C31H23N3O; C, 82.10; H, 5.11; N, 9.26. Found: C, 82.00; H, 
5.49; N, 9.24. 
 
Cyclization of 3b and 9b. General procedure 
3b (476 mg, 1 mmol), Pd2(dba)3 (25 mg, 0.024 mmol, 2.4% mol) and DBU (0.30 mL) were 
placed in a 25 mL round-bottomed flask. The flask was capped with a rubber septum and dry 
DMF (15 mL) was added through a syringe. The mixture was flushed with argon for 30 min and 
P(t-Bu)3 in toluene (19.4 mg, 0.096 mmol, 0.12 mL) was added in one portion. The mixture was 
stirred for another 10 min at room temperature then the yellow solution was 3 h stirred in an oil 
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bath at 130oC until starting material disappeared. After cooling, the deep brown solution was 
poured into water (25 mL). The mixture was extracted with toluene (2 x 25 mL). The organic 
phase was washed with saturated aqueous NaCl solution and dried over anhydrous MgSO4. After 
evaporation, the residue was treated with chloroform (5 mL) and MeOH was added dropwise on 
sonication in a cold water bath. The precipitate was filtered off.  
1,3-Diphenyl-3H-indeno[1,2,3-de]pyrazolo[3,4-b]quinoline (2). Orange crystals; yield 285 mg 
(72%); mp = 212−214 °C; IR (KBr) 3111, 1599, 1499, 1447, 1403, 1387, 753, 689 cm-1; UV 
(MeCN): λmax [nm] = 437 nm; Fluorescence (MeCN) λmax [nm] = 550; 1H NMR (300 MHz, 
CDCl3) δ 6.90 (dt, 1H, J = 7.5, 0.6 Hz), 7.03 (td, 1H, J  = 7.5, 1.2 Hz), 7.31 (dd, 1H, J = 7.5, 1.2 
Hz), 7.34 (t, 1H, J = 7.2 Hz), 7.55−7.63 (m, 5H), 7.72 (dd, 2H, J = 4.8, 1.2 Hz), 7.75−7.83 (m, 
3H), 7.95−8.00 (m, 1H), 8.53 (d, 2H, J = 8.7 Hz); 13C NMR (75 MHz, CDCl3) δ 112.81, 118.92, 
121.61, 121.65, 123.98, 125.82, 127.72, 127.93, 128.27, 128.54, 129.01, 129.37, 129.90, 130.22, 
132.30, 133.90, 137.35, 138.34, 139.82, 139.87, 140.98, 144.79, 145.90, 153.07; MS (FAB) m/z 
396 (M++H); Anal. Calcd. for C28H17N3: C, 85.04; H, 4.33; N,10.63; found: C, 85.11; H, 4.37; N, 
10.48.  
7-Ethyl-1-(4-methoxyphenyl)-3-phenyl-3H-indeno[1,2,3-de]pyrazolo[3,4-b]quinoline (11). 
Light yellow crystals; yield 170 mg (75%); mp = 200–203 °C; 1H NMR (300 MHz, CDCl3) δ 
1.45 (t, 3H, J = 7.5 Hz), 3.21 (q, 2H, J = 7.5 Hz), 3.96 (s, 3H, OCH3), 7.08 (dd, 1H, J = 1.5, 0.9 
Hz), 7.10 (d, 1H, J = 0.6 Hz), 7.13 (d, 2H, J = 8.7 Hz), 7.30–7.42 (m, 2H), 7.57 (t, 2H, J = 7.5 
Hz), 7.60 (d, 1H, J = 8.7 Hz), 7.73 (d, 2H, J = 8.7 Hz), 7.90 (d, 1H, J = 7.8 Hz), 7.96 (d, 1H, J = 
9.0 Hz), 8.54 (d, 2H, J = 8.7 Hz); 13C NMR (75 MHz, CDCl3) δ ; 14.84, 26.74, 55.50, 112.50, 
113.97, 121.51, 123.73, 124.18, 125.59, 126.52, 126.93, 128.03, 128.51, 128.97, 129.78, 131.50, 
133.85, 135.17, 137.49, 138.82, 139.59, 139.99, 141.06, 143.73, 145.57, 152.69, 160.56; Anal. 
Calcd. for C31H23N3O; C, 82.10; H, 5.11; N, 9.26. Found: C, 82.00; H, 5.27; N, 9.34. 
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